Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.43 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.43 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.43 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.40 |
| ▸ | P2RY2 | P41231 | 5/20 | 0.40 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23808332 | 1.00 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3POLB | |
| SCHEMBL16108405 | 1.00 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3POLB | |
| SCHEMBL23808336 | 0.89 | P2RY6 (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3POLB | |
| SCHEMBL21345265 | 0.88 | P2RY6 (0.42) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL22475111 | 0.84 | POLB (0.39) | SLC28A1SLC28A2SLC29A1SLC28A3POLB | |
| SCHEMBL21333519 | 0.84 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL23622227 | 0.84 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL16144608 | 0.84 | POLB (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3POLB | |
| SCHEMBL16644423 | 0.84 | POLB (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3POLB | |
| SCHEMBL20611194 | 0.83 | POLB (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2981542-B1 | 2',4'-FLUORO NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2021-09-15 | — | — | EP | disclosed |
| EP-2981542-B1 | 2',4'-FLUORO NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2021-09-15 | — | — | EP | disclosed |
| US-9187515-B2 | 2′,4′-fluoro nucleosides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187515-B2 | 2′,4′-fluoro nucleosides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2015-11-17 | — | — | US | disclosed |
| WO-2014165542-A1 | 2',4'-FLUORO NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140294769-A1 | 2',4'-FLUORO NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC | 2014-10-02 | — | — | US | disclosed |
| US-20140294769-A1 | 2',4'-FLUORO NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140294769-A1 | 2',4'-FLUORO NUCLEOSIDES FOR THE TREATMENT OF HCV | SLC29A1, SLC28A1, SLC10A1 | SLC28A1 2/4885SLC28A2 5/4885SLC29A1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.